Navigation Links
CREON(R) (pancrelipase) Delayed-Release Capsules Improves Digestive Outcomes In Adults With Chronic Pancreatitis
Date:10/26/2009

CFA) as compared to the placebo group. CFA is calculated based on measures of fat ingestion and fat excretion; assessing the CFA of a patient is another way to measure the absorption of fat as a percentage of fat intake in patients being tested for EPI. The primary efficacy endpoint was the change in CFA from baseline to the end of the double-blind treatment period. The CFA improved by 32.1% in the CREON® group compared to 8.8% in the placebo group, representing a statistically significant difference between CREON® and placebo (P<0.0001).

"These data add to the growing body of evidence supporting the efficacy and safety profile of CREON® across multiple conditions while also providing clarity around the appropriate dosing of pancreatic enzyme replacement therapy in these patients," said Elizabeth M. Mutisya, M.D., Vice President of U.S. Medical Affairs and Chief Medical Officer at Solvay Pharmaceuticals, Inc. "These CREON® study results are encouraging as dosing of pancreatic enzymes for patients with EPI due to CP or pancreatic surgery has not previously been well defined."

Study Details

The double-blind, randomized, placebo-controlled, two-arm, parallel-group study conducted in the United States, Eastern and Central Europe, examined the efficacy and safety of CREON® 12,000-lipase unit capsules in 52 adults aged 18 years or older with EPI due to CP or pancreatic surgery. Patients were randomized to receive CREON® 12,000-lipase unit capsules at a dose of 72,000 lipase units per main meal and 36,000 lipase units per snack or matching placebo. EPI was confirmed in all subjects through direct pancreatic function testing such as, secretin tests or fecal elastase (< 100 micrograms/g), 72-hour fecal fat determination (> 15 g/day) or pancreatectomy more than 180 days prior to study enrollment.

Upon analysis of the primary efficacy results, the mean CFA increased by 32.1% in t
'/>"/>

SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
2. CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis
3. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
4. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
5. GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
6. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
7. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
8. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
9. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
10. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
11. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... 2015 , ... Carey Danis & Lowe comments on a new ... Virginia federal court. The court document outlined the judge’s plan to consolidate 26 vaginal ... Carey Danis & Lowe is a personal injury law firm with headquarters in St. ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable source of ... native of Detroit, MI, Kid Rock, is hitting the road again this summer in what ... and hip hop superstar kicked off his summer tour this year at the XFINITY Theatre ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... Texas have launched a ‘responsive design’ website to inform potential sinus surgery patients ... them. , The website includes information about a wide variety of ENT issues ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... pleased to announce it’s own Debby Mann, CPC, RCC, ROCC, Coding Documentation and ... Summit with the Special Recognition Award for her contribution to the RBMA Coding ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand ... “Grand Terrace Health Care Center.” Each year, Medicare ranks care centers around the ... best facility for their needs. Grand Terrace prides itself on quality in each ...
Breaking Medicine News(10 mins):Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 3Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2
... of Pennsylvania School of Medicine have created the first ... a mutation known to produce disease in people, an ... in the October issue of Human Molecular Genetics. ... of vision loss in elderly people, affecting more than ...
... Oct. 9 The following was released,today by the ... MR. TENPAS: Good morning. I am Ronald ... Natural Resources Division here at the,Department of Justice. ... administrator for Enforcement and Compliance Assurance., We ...
... wane over time, study finds , , TUESDAY, Oct. 9 ... who,ve lost weight keep it off, new research suggests. ... of the maintenance programs wears off over time, suggesting ... maintain healthier lifestyles. , "We were excited ...
... a potentially novel way to fight colorectal cancer using ... cancer cells, unlike current treatments that bind to the ... cause unwanted side effects. , In laboratory studies ... system proved able to specifically target colon cancer cells, ...
... NEW YORK, Oct. 9 Highlands Acquisition Corp.,(Amex: HIA.U), ... public offering (the "IPO") of 12,000,000 units. Each unit ... which entitles the holder to,purchase one share of common ... $10.00 per unit, generating gross proceeds of $120,000,000 to ...
... age of 12 currently drink alcohol, according to a ... Services Administration. While the majority of people who drink ... in the expression of violence. , By far the ... violent behavior involves alcohol, says Dr. Jeff Kretschmar, a ...
Cached Medicine News:Health News:Model to study age-related macular degeneration could pave way for better treatment 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 3Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 4Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 5Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 6Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 7Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 8Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 9Health News:Maintenance Treatment Helps Kids Keep Weight Off 2Health News:Maintenance Treatment Helps Kids Keep Weight Off 3Health News:Maintenance Treatment Helps Kids Keep Weight Off 4Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 3
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: